the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma (HCC)
Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma
Sponsor: Shandong New Time Pharmaceutical Co., LTD
A PHASE2/PHASE3 clinical study on Hepatocellular Carcinoma, this trial is actively recruiting participants. The trial is conducted by Shandong New Time Pharmaceutical Co., LTD and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shandong New Time Pharmaceutical Co., LTD
For direct contact, visit the study record on ClinicalTrials.gov .